The main phase of the trial is planned for 2026, and the research period will end in 2031. By 2026, the company must find three new volunteers diagnosed with severe quadriplegia, where all limbs are paralyzed due to severe spinal cord injuries or amyotrophic lateral sclerosis. (ALS).
There is no confirmation yet that Neuralink has received permission from regulatory authorities; The data in the clinical trial database says nothing. But this is still an indication of Neuralink’s intention to increase the number of users of the company’s neural interfaces.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
